EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Relationship between Anti–SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination

Yuichiro Takeshita iD, Yasuo To iD, Yusuke Kurosawa, Toru Kinouchi, Kota Tsuya iD, Yuji Tada, Kenji Tsushima

ImmunoHorizons · 2023

DOI: 10.4049/immunohorizons.2200093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, 2023. Verfasst von Yuichiro Takeshita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan. Hauptthemen laut MEDLINE: COVID-19, Oxygen, Antibodies, Viral, Interferons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the effectiveness of vaccination at preventing hospitalization and severe coronavirus disease (COVID-19) has been reported in numerous studies, the detailed mechanism of innate immunity occurring in host cells by breakthrough infection is unclear. One hundred forty-six patients were included in this study. To determine the effects of vaccination and past infection on innate immunity following SARS-CoV-2 infection, we analyzed the relationship between anti–SARS-CoV-2 S Abs and biomarkers associated with the deterioration of COVID-19 (IFN-λ3, C-reactive protein, lactate dehydrogenase, ferritin, procalcitonin, and D-dimer). Anti-S Abs were classified into two groups according to titer: high titer (≥250 U/ml) and low titer (<250 U/ml). A negative correlation was observed between anti–SARS-CoV-2 S Abs and IFN-λ3 levels (r = −0.437, p < 0.001). A low titer of anti–SARS-CoV-2 S Abs showed a significant association with oxygen demand in patients, excluding aspiration pneumonia. Finally, in a multivariate analysis, a low titer of anti–SARS-CoV-2 S Abs was an independent risk factor for oxygen demand, even after adjusting for age, sex, body mass index, aspiration pneumonia, and IFN-λ3 levels. In summary, measuring anti–SARS-CoV-2 S Abs and IFN-λ3 may have clinical significance for patients with COVID-19. To predict the oxygen demand of patients with COVID-19 after hospitalization, it is important to evaluate the computed tomography findings to determine whether the pneumonia is the result of COVID-19 or aspiration pneumonia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19OxygenAntibodies, ViralInterferonsHumansPneumonia, AspirationSARS-CoV-2InterleukinsInterferon Lambda

Substanzen

OxygenAntibodies, ViralInterferonsinterferon-lambda, humanInterleukinsInterferon Lambda

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Itabashiku, Tokyo, Japan; and.
  • Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.

ORCID-Profile: Yuichiro Takeshita, Yasuo To, Kota Tsuya

Zitieren

APA

Takeshita, Y., To, Y., Kurosawa, Y., Kinouchi, T., Tsuya, K., Tada, Y., & Tsushima, K. (2023). Relationship between Anti–SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination. ImmunoHorizons. https://doi.org/10.4049/immunohorizons.2200093

Vancouver

Takeshita Y, To Y, Kurosawa Y, Kinouchi T, Tsuya K, Tada Y, et al. Relationship between Anti–SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination. ImmunoHorizons. 2023. doi:10.4049/immunohorizons.2200093

BibTeX
@article{Takeshita2023,
  author = {Takeshita, Yuichiro and To, Yasuo and Kurosawa, Yusuke and Kinouchi, Toru and Tsuya, Kota and Tada, Yuji and Tsushima, Kenji},
  title = {Relationship between Anti–SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination},
  journal = {ImmunoHorizons},
  year = {2023},
  doi = {10.4049/immunohorizons.2200093}
}
Kostenlos starten →